Researchers have found that mice given fingolimod, a drug approved by the US Food and Drug Administration for treatment of multiple sclerosis, had enhanced 'memory extinction' of previous experiences that had caused pain.
If the effects of the drug apply to humans, it may offer new treatment options for sufferers of post-traumatic stress, phobias and eating disorders.
Fingolimod, available as a tablet under the brand name Gilenya, treats remitting forms of MS by suppressing the immune system.
When fed to mice, fingolimod crossed the blood-brain barrier and was faster at extinguishing "previously acquired fear memories".
The mice were put in a chamber where their feet were exposed to a mild electric shock, and when returned to the cage the extent to which they froze to the spot was recorded as a measure of anxiety.
This complete lack of movement, known as "freezing" - a fear response in rodents providing a good indication of memory - subsided rapidly after receiving the drug.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
